Original Research Article
Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s DiseaseCombarros O.a · García-Román M.b · Fontalba A.b · Fernández-Luna J.L.b · Llorca J.c · Infante J.a · Berciano J.a
aUnit of Neurology and bUnit of Molecular Genetics, ‘Marqués de Valdecilla’ University Hospital, University of Cantabria, and cDivision of Preventive Medicine, University of Cantabria School of Medicine, Santander, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The H63D mutation in the hemochromatosis gene (HFE) has recently been considered as a risk factor in Alzheimer`s disease (AD) with advancing age at onset of the disease, independently of the apolipoprotein E (ApoE) Ε4 allele effect. We examined the distribution of the H63D mutation and ApoE genotypes as a function of age at AD onset in 328 patients with sporadic AD. Our data show that the mutant H63D allele potentially interacts with the ApoE Ε4 allele to significantly reduce age at onset of AD compared to ApoE Ε4 carriers alone, but has no effect on age at onset in ApoE Ε4 non-carriers.
© 2003 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.